MapleStory’s Neo: Light's Wrath Update Unveils New Boss Seren and Hotel Arcus Questline
22.7.2021 16:00:00 EEST | Business Wire | Press release
MapleStory , the iconic free-to-play global MMORPG from Nexon, has launched Neo: Light’s Wrath, Part Two of the massive summer content update that offers all new desert area, Hotel Arcus, offering new quests available to players level 270 and above. The Neo: Light’s Wrath update also adds the new Boss Seren and continues the Neo Castle, Tera Burning and Burning World Events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005292/en/
MapleStory’s Neo: Light's Wrath Update Unveils New Boss Seren and Hotel Arcus Questline (Photo: Business Wire)
Hidden secrets of the ancient gods will be unveiled in the Hotel Arcus desert area which has opened for players who have reached Level 270 and have completed the 5th job advancement along with the “[Cernium (After)] Defensive Tactics” quest. Following clues from the ancient gods will reveal the mysteries of the Hotel Arcus, offering a series of quests that will reward players with the Sacred Symbol: Arcus upon completion. After all Hotel Arcus quests are completed players can perform daily quests for Archelon in the Hotel Arcus Saloon that will reward Sacred Symbol: Arcus.
With the battle at Cernium at its end, Seren has emerged as god incarnate, wielding the power of the ancient gods. Players level 265 who have completed the 5th job advancement along with the “[Cernium (After)] Defensive Tactics” quest are able to test their strength against the powerful new boss Seren by entering a special portal in the Cernium Royal Palace Main Hall. By defeating Seren, players have the chance to earn Mitra’s Nodestone and Mitra’s Rage Emblem, part of the Pitched Boss Set. Mitra’s Nodestone unlocks the Solar Crest skill when used and Mitra’s Rage Emblem provides +40 primary stat/secondary stat for your class and +5 Attack/Magic Attack. Mitra’s Rage is tradable until equipped and can be equipped at level 200.
The Neo: Light’s Wrath Update continues the Neo Castle and Tera Burning and Burning World Events:
Neo Castle Event: Neo Castle is an area shrouded in mystery and was formed when Maple World and Grandis World combined, creating a space to enjoy a series of new events and mini-games including new ways to earn NEO currency with the following features and shops available:
- Neo Stone Shop: Players can exchange Neo Stones for a variety of items that can be used to enhance equipment and boost character growth
- Neo Gem Shop: Neo Gems are earned by playing one of the many new mini-games, and can be used to buy special cosmetic items
- Neo Core Shop: Neo Cores can be collected by defeating bosses and can be used to purchase a variety of enhancement items
- Neo Meso Shop: The Meso shop is stocked full of useful items and cosmetic items that can be purchased using Mesos
Burning World and Tera Burning Plus: Burning World and Tera Burning Plus events continue to support speedy player growth, allowing players to create and designate burning characters who will gain 1+2 levels each time they level up, to Lv. 150 and Lv. 200 respectively, receive additional level-up rewards, and earn the 17-Star Unique Absolab weapon if your Tera Burning Plus character reaches Lv. 220. Burning World Leap will begin August 25 and characters Lv. 150 and above will be able to leap to any non-Reboot world in their region.
To learn more about MapleStory , please visit http://maplestory.nexon.net
Assets - Neo: Light’s Wrath Video - Artwork
Social Media: TikTok / Twitter / Instagram / Twitch / Facebook / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005292/en/
Contact information
Brian Klotz
Nexon America
pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom